Agilent Technologies (A) 36.77 $A
What Lies Ahead for Agilent Technologies' (A) Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 12:40PM CST
Agilent Technologies Inc. (A) is set to report fourth-quarter fiscal 2015 results on Nov 16. Last quarter, the company posted a 7.32% positive earnings surprise.
STOR: 21.65 (-0.17), A: 36.77 (-0.72), SDLP: 10.80 (+0.91), SIG: 136.42 (-4.72)
Global Mass Spectrometry Market 2015-2019
M2 - Thu Nov 12, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hkntz7/global_mass) has announced the addition of the "Global Mass Spectrometry Market 2015-2019" report to their offering. The global mass spectrometry market to grow at a CAGR of 8.34% over the period 2014-2019. The report, Global Mass Spectrometry Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, APAC and ROW; it also covers the landscape of the global mass spectrometry market and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market. There are signals that indicate that the market will witness a rise in mergers and acquisitions as well as partnerships between mass spectrometer companies and diagnostic companies in an effort to gain market share and develop awareness in the clinical communities regarding the products offered by such companies. According to the report, the use of these instruments in clinical sciences for preclinical tests of newfound drugs prior to their administration to humans has gained widespread popularity over the years. Further, the report states that as spectrometers are large and complex, they also use software for various measurement procedures. Therefore, companies need to invest heavily in providing training to their employees in how to use mass spectrometers effectively. To calculate the market size, the report considers revenue generated through various segments based on: - Types - Applications - Geography The market is divided into the following segments based on type: - Triple quadruple mass spectrometry - Time of flight mass spectrometry - MALDI-TOF mass spectrometry - Ion trap mass spectrometry - Fourier transform mass spectrometry - Single quadruple mass spectrometry The market is divided into the following segments based on application: - Biopharmaceuticals - Industrial Applications - Academia Key vendors - Agilent Technologies - Bruker - Danaher - Thermo Fisher Scientific - Waters Other prominent vendors - Bio-Rad Laboratories - Jeol - Perkin Elmer - Rigaku - Shimadzu For more information visit http://www.researchandmarkets.com/research/hk...lobal_mass
A: 36.77 (-0.72), DHR: 93.54 (-0.55)
Ametek Increases Share Repurchase Authorization by $350M
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 12:25PM CST
Ametek Inc. (AME) recently increased the share repurchase authorization by $350 million.
AME: 53.76 (-0.33), A: 36.77 (-0.72), GOOGL: 740.07 (-16.46), MXL: 16.08 (-0.20)
Complete Guide to Diagnostic Distribution in China - Profiles of all Three Types of Distribution Alternatives are Included in their Distribution Editions
M2 - Wed Nov 11, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/txlwr5/complete_guide_to) has announced the addition of the "Complete Guide to Diagnostic Distribution in China" report to their offering. The Complete Guides to Diagnostic Distribution series are excerpts from their detailed market research studies. They are available for China, India, Brazil and Mexico. Distribution in all four countries is done by a mixture of international firms which also handle the products of other companies, by local manufacturers who add distribution of other product lines to their offerings and by local IVD distributors who put together a group of companies that do not have a local office. Profiles of all three types of distribution alternatives are included in their Distribution Editions. The full reports are sold to the top multinational diagnostic firms, but their Distribution Editions are designed for small to medium sized firms that are primarily interested in finding a distributor. They include a Country Summary section that reviews the healthcare system, private vs. public segmentation, medical insurance, the laboratory structure, product registration and any unusual features of the local market. Then there are the Profiles, divided into three sections: International Manufacturers, Domestic Manufactures and Domestic Distributors. Mexico is the one exception in that as a NAFTA country there is so little domestic manufacturing that the few firms that do some manufacturing are included under distributors. Key Topics Covered: 1. Country Summary 2. International Manufacturer Profiles 3. Domestic Manufacturer Profiles 4. Distributor Profiles Companies Mentioned - 3V Bioengineering - Abbott Laboratories - Accubio Tech - Acon Biotech - Adaltis - Addcare Bio-Tech - Advanced Clinical Laboratory Science (Acls) - Affymetrix - Agilent Technologies - Ai De Diagnostic (Ind) - Ailex Technology - Alere - Alt Biotech - Ausbio Laboratories - Bio-Asia Diagnostics - Biochem Group For more information visit http://www.researchandmarkets.com/research/tx...e_guide_to
ABT: 43.96 (-0.23), A: 36.77 (-0.72)
Future Horizons and Growth Strategies in the Global Beta-2 Microglobulin Testing Market 2016: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/6npmbs/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Beta-2 Microglobulin Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the ?-2 Microglobulin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/6n...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Future Horizons and Growth Strategies in the Global Pap Smear/HPV Testing Market 2016: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmkv/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Pap Smear/HPV Testing Market: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the Pap Smear/HPV testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/59...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
2016 Future Horizons and Growth Strategies in the Global Occult Blood Testing Market: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/x5dlnf/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Occult Blood Testing Market: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the Occult Blood testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/x5...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Future Horizons and Growth Strategies in the Global CEA Testing Market 2016: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/vspfdh/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global CEA Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the CEA testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/vs...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Future Horizons and Growth Strategies in the Global CA Tumor Markers Testing Market 2016: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/wbh4hk/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global CA Tumor Markers Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/wb...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
2016 Future Horizons and Growth Strategies in the Global Prostatic Acid Phosphatase Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/r2klfd/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Prostatic Acid Phosphatase Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the PAP testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/r2...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Will ADT Corp. (ADT) Miss Q4 Earnings on Margin Pressure?
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 10:30AM CST
The ADT Corporation (ADT) is scheduled to report its fourth-quarter fiscal 2015 results before the opening bell on Nov 11.
AQXP: 12.85 (+0.14), A: 36.77 (-0.72), PLKI: 53.76 (-0.80), ADT: 33.81 (+0.06)
Will DTS (DTSI) Beat Estimates This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 5:43PM CST
We expect DTS Inc. (DTSI) to beat expectations when it reports third-quarter 2015 results on Nov 9.
DTSI: 25.21 (-0.30), PNNT: 6.52 (+0.03), A: 36.77 (-0.72), AEE: 43.13 (-0.37)
SunEdison Semiconductor (SEMI): What's Up This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 5:41PM CST
SunEdison Semiconductor Limited (SEMI) is slated to report third-quarter 2015 results on Nov 9.
A: 36.77 (-0.72), ZAYO: 22.81 (-1.42), SEMI: 9.51 (-0.11), AEE: 43.13 (-0.37)
What's in the Cards for Model N (MODN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 5:24PM CST
Model N, Inc. (MODN) is scheduled to report fourth-quarter fiscal 2015 results on Nov 9.
SAP: 77.96 (-1.18), MODN: 10.38 (+0.11), AUPH: 2.76 (+0.01), A: 36.77 (-0.72)
Agilent Technologies enters into instrument control exchange agreement with Thermo Fisher Scientific
M2 - Fri Nov 06, 5:44AM CST
Life science company Agilent Technologies (NYSE:A) revealed on Thursday that it has entered into a formal agreement to exchange instrument controls to improve the productivity and user experience of customers using software and instruments with Thermo Fisher Scientific.
A: 36.77 (-0.72)
Agilent Technologies Signs Instrument Control Exchange Agreement with Thermo Fisher Scientific
M2 - Fri Nov 06, 3:54AM CST
Agilent Technologies Inc. (NYSE: A) today announced a formal agreement with Thermo Fisher Scientific to exchange instrument controls to improve the productivity and user experience of customers using software and instruments from both companies.
A: 36.77 (-0.72)
Itron (ITRI) Misses on Q3 Earnings and Revenues, Shares Fall
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 1:25PM CST
Itron???s (ITRI) third-quarter earnings missed the Zacks Consensus Estimate.
AMBA: 50.35 (-2.04), ITRI: 33.67 (+0.36), A: 36.77 (-0.72), ACIW: 23.36 (-0.53)
Teradata (TDC) to Report Q3 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 2:20PM CST
Teradata Corp. (TDC) is set to report third-quarter 2015 results on Nov 5.
IBM: 131.75 (-1.29), A: 36.77 (-0.72), TDC: 26.12 (-0.46), ORCL: 37.30 (-1.33)
What Lies Ahead for Agilent Technologies' (A) Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 12:40PM CST
Agilent Technologies Inc. (A) is set to report fourth-quarter fiscal 2015 results on Nov 16. Last quarter, the company posted a 7.32% positive earnings surprise.
STOR: 21.65 (-0.17), A: 36.77 (-0.72), SDLP: 10.80 (+0.91), SIG: 136.42 (-4.72)
Global Mass Spectrometry Market 2015-2019
M2 - Thu Nov 12, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hkntz7/global_mass) has announced the addition of the "Global Mass Spectrometry Market 2015-2019" report to their offering. The global mass spectrometry market to grow at a CAGR of 8.34% over the period 2014-2019. The report, Global Mass Spectrometry Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, APAC and ROW; it also covers the landscape of the global mass spectrometry market and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market. There are signals that indicate that the market will witness a rise in mergers and acquisitions as well as partnerships between mass spectrometer companies and diagnostic companies in an effort to gain market share and develop awareness in the clinical communities regarding the products offered by such companies. According to the report, the use of these instruments in clinical sciences for preclinical tests of newfound drugs prior to their administration to humans has gained widespread popularity over the years. Further, the report states that as spectrometers are large and complex, they also use software for various measurement procedures. Therefore, companies need to invest heavily in providing training to their employees in how to use mass spectrometers effectively. To calculate the market size, the report considers revenue generated through various segments based on: - Types - Applications - Geography The market is divided into the following segments based on type: - Triple quadruple mass spectrometry - Time of flight mass spectrometry - MALDI-TOF mass spectrometry - Ion trap mass spectrometry - Fourier transform mass spectrometry - Single quadruple mass spectrometry The market is divided into the following segments based on application: - Biopharmaceuticals - Industrial Applications - Academia Key vendors - Agilent Technologies - Bruker - Danaher - Thermo Fisher Scientific - Waters Other prominent vendors - Bio-Rad Laboratories - Jeol - Perkin Elmer - Rigaku - Shimadzu For more information visit http://www.researchandmarkets.com/research/hk...lobal_mass
A: 36.77 (-0.72), DHR: 93.54 (-0.55)
Ametek Increases Share Repurchase Authorization by $350M
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 12:25PM CST
Ametek Inc. (AME) recently increased the share repurchase authorization by $350 million.
AME: 53.76 (-0.33), A: 36.77 (-0.72), GOOGL: 740.07 (-16.46), MXL: 16.08 (-0.20)
Complete Guide to Diagnostic Distribution in China - Profiles of all Three Types of Distribution Alternatives are Included in their Distribution Editions
M2 - Wed Nov 11, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/txlwr5/complete_guide_to) has announced the addition of the "Complete Guide to Diagnostic Distribution in China" report to their offering. The Complete Guides to Diagnostic Distribution series are excerpts from their detailed market research studies. They are available for China, India, Brazil and Mexico. Distribution in all four countries is done by a mixture of international firms which also handle the products of other companies, by local manufacturers who add distribution of other product lines to their offerings and by local IVD distributors who put together a group of companies that do not have a local office. Profiles of all three types of distribution alternatives are included in their Distribution Editions. The full reports are sold to the top multinational diagnostic firms, but their Distribution Editions are designed for small to medium sized firms that are primarily interested in finding a distributor. They include a Country Summary section that reviews the healthcare system, private vs. public segmentation, medical insurance, the laboratory structure, product registration and any unusual features of the local market. Then there are the Profiles, divided into three sections: International Manufacturers, Domestic Manufactures and Domestic Distributors. Mexico is the one exception in that as a NAFTA country there is so little domestic manufacturing that the few firms that do some manufacturing are included under distributors. Key Topics Covered: 1. Country Summary 2. International Manufacturer Profiles 3. Domestic Manufacturer Profiles 4. Distributor Profiles Companies Mentioned - 3V Bioengineering - Abbott Laboratories - Accubio Tech - Acon Biotech - Adaltis - Addcare Bio-Tech - Advanced Clinical Laboratory Science (Acls) - Affymetrix - Agilent Technologies - Ai De Diagnostic (Ind) - Ailex Technology - Alere - Alt Biotech - Ausbio Laboratories - Bio-Asia Diagnostics - Biochem Group For more information visit http://www.researchandmarkets.com/research/tx...e_guide_to
ABT: 43.96 (-0.23), A: 36.77 (-0.72)
Future Horizons and Growth Strategies in the Global Beta-2 Microglobulin Testing Market 2016: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/6npmbs/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Beta-2 Microglobulin Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the ?-2 Microglobulin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/6n...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Future Horizons and Growth Strategies in the Global Pap Smear/HPV Testing Market 2016: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmkv/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Pap Smear/HPV Testing Market: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the Pap Smear/HPV testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/59...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
2016 Future Horizons and Growth Strategies in the Global Occult Blood Testing Market: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/x5dlnf/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Occult Blood Testing Market: Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the Occult Blood testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/x5...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Future Horizons and Growth Strategies in the Global CEA Testing Market 2016: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/vspfdh/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global CEA Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. This report presents a detailed analysis of the CEA testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/vs...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Future Horizons and Growth Strategies in the Global CA Tumor Markers Testing Market 2016: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/wbh4hk/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global CA Tumor Markers Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/wb...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
2016 Future Horizons and Growth Strategies in the Global Prostatic Acid Phosphatase Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities
M2 - Tue Nov 10, 10:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/r2klfd/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the Global Prostatic Acid Phosphatase Testing Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the PAP testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion For more information visit http://www.researchandmarkets.com/research/r2...016_future
A: 36.77 (-0.72), CPHD: 33.95 (-0.18), DHR: 93.54 (-0.55)
Will ADT Corp. (ADT) Miss Q4 Earnings on Margin Pressure?
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 10:30AM CST
The ADT Corporation (ADT) is scheduled to report its fourth-quarter fiscal 2015 results before the opening bell on Nov 11.
AQXP: 12.85 (+0.14), A: 36.77 (-0.72), PLKI: 53.76 (-0.80), ADT: 33.81 (+0.06)
Will DTS (DTSI) Beat Estimates This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 5:43PM CST
We expect DTS Inc. (DTSI) to beat expectations when it reports third-quarter 2015 results on Nov 9.
DTSI: 25.21 (-0.30), PNNT: 6.52 (+0.03), A: 36.77 (-0.72), AEE: 43.13 (-0.37)
SunEdison Semiconductor (SEMI): What's Up This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 5:41PM CST
SunEdison Semiconductor Limited (SEMI) is slated to report third-quarter 2015 results on Nov 9.
A: 36.77 (-0.72), ZAYO: 22.81 (-1.42), SEMI: 9.51 (-0.11), AEE: 43.13 (-0.37)
What's in the Cards for Model N (MODN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 5:24PM CST
Model N, Inc. (MODN) is scheduled to report fourth-quarter fiscal 2015 results on Nov 9.
SAP: 77.96 (-1.18), MODN: 10.38 (+0.11), AUPH: 2.76 (+0.01), A: 36.77 (-0.72)
Agilent Technologies enters into instrument control exchange agreement with Thermo Fisher Scientific
M2 - Fri Nov 06, 5:44AM CST
Life science company Agilent Technologies (NYSE:A) revealed on Thursday that it has entered into a formal agreement to exchange instrument controls to improve the productivity and user experience of customers using software and instruments with Thermo Fisher Scientific.
A: 36.77 (-0.72)
Agilent Technologies Signs Instrument Control Exchange Agreement with Thermo Fisher Scientific
M2 - Fri Nov 06, 3:54AM CST
Agilent Technologies Inc. (NYSE: A) today announced a formal agreement with Thermo Fisher Scientific to exchange instrument controls to improve the productivity and user experience of customers using software and instruments from both companies.
A: 36.77 (-0.72)
Itron (ITRI) Misses on Q3 Earnings and Revenues, Shares Fall
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 1:25PM CST
Itron???s (ITRI) third-quarter earnings missed the Zacks Consensus Estimate.
AMBA: 50.35 (-2.04), ITRI: 33.67 (+0.36), A: 36.77 (-0.72), ACIW: 23.36 (-0.53)
Teradata (TDC) to Report Q3 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 2:20PM CST
Teradata Corp. (TDC) is set to report third-quarter 2015 results on Nov 5.
IBM: 131.75 (-1.29), A: 36.77 (-0.72), TDC: 26.12 (-0.46), ORCL: 37.30 (-1.33)
